Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759135 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
A Phase 2 study, sponsored by Nymox Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00759135: Completed Phase 2 study, sponsored by Nymox Corporation.
NCT00759135 is a Phase 2 study that has completed, run by Nymox Corporation. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00759135, a Phase 2 study, has completed, sponsored by Nymox Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
Interventions
- DRUG 2.5 mg NX-1207
- DRUG 0.125 mg NX-1207
- DRUG finasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00759135 record still lists
NCT00759135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 3 interventions - of which 2.5 mg NX-1207 is the first listed.
NCT00759135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00759135 about?
NCT00759135 is a clinical study titled "Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)". This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
What is the current status of trial NCT00759135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2007-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00759135?
The interventions under investigation include: 2.5 mg NX-1207 (DRUG), 0.125 mg NX-1207 (DRUG), finasteride (DRUG).
Who is sponsoring clinical trial NCT00759135?
This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00759135's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia